Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Registry Hub

Therapeutic Classification

jak inhibitor Registry

Clinical reference for jak inhibitor medications. Access safety monographs, dosing adjustments, and drug-drug interactions for all registered brand names and generics in this class.

Registered Medications (jak inhibitor)

This therapeutic registry is dynamically synthesized from professional clinical sources. Listing of a medication does not imply equivalence; refer to individual monographs for head-to-head pharmacological data.

MedicationTherapeutic ClassMaternal Safety

BARICITINIB

Comprehensive clinical and safety monograph for BARICITINIB (BARICITINIB).

JAK Inhibitor

caution

CIBINQO

Comprehensive clinical and safety monograph for CIBINQO (CIBINQO).

JAK Inhibitor

caution

FILKRI

Comprehensive clinical and safety monograph for FILKRI (FILKRI).

JAK Inhibitor

caution

INREBIC

Comprehensive clinical and safety monograph for INREBIC (INREBIC).

JAK Inhibitor

caution

LITFULO

Comprehensive clinical and safety monograph for LITFULO (LITFULO).

JAK Inhibitor

caution

OPZELURA

Comprehensive clinical and safety monograph for OPZELURA (OPZELURA).

JAK Inhibitor (Topical)

caution

REVUFORJ

Comprehensive clinical and safety monograph for REVUFORJ (REVUFORJ).

JAK Inhibitor

caution

Ruxolitinib

Strong CYP3A4 inhibitors may increase levels Can cause serious infections and myelosuppression.

JAK Inhibitor

avoid

TOFACITINIB

Strong CYP3A4 inhibitors may increase levels Can cause serious infections and increased risk of malignancy.

JAK Inhibitor

avoid

TOFACITINIB CITRATE

Strong CYP3A4 inhibitors may increase levels Can cause serious infections and increased risk of malignancy.

JAK Inhibitor

avoid

TOFIDENCE

Comprehensive clinical and safety monograph for TOFIDENCE (TOFIDENCE).

JAK inhibitor

caution

VIVJOA

Comprehensive clinical and safety monograph for VIVJOA (VIVJOA).

JAK Inhibitor

caution

VONJO

Comprehensive clinical and safety monograph for VONJO (VONJO).

JAK Inhibitor

caution

XELJANZ

Comprehensive clinical and safety monograph for XELJANZ (XELJANZ).

JAK Inhibitor

caution

XELJANZ XR

Comprehensive clinical and safety monograph for XELJANZ XR (XELJANZ XR).

JAK Inhibitor

caution